Quotient Sciences, a CDMO, reports that it has installed Centillion’s™ Biofoundry-in-a-Box (BiaB™), a multi-product GMP platform technology for end-to-end RNA manufacture. BiaB is a modular, integrated, and automated RNA-micro factory that enables the processing of various RNA-based products, including messenger RNA (mRNA) and self-amplifying RNA (saRNA), and has the potential to significantly reduce the time it takes to bring RNA therapies to market, according to officials at Quotient.
Continuous flow-based manufacturing
Centillion’s BiaB technology offers continuous flow-based manufacture and encapsulation of RNA, and more flexibility with higher productivities at smaller footprints, noted Paul Ryan, SVP and head of candidate development at Quotient, adding that it also enables larger quantities of RNA drug substance to be split and encapsulated in portions to create a series of RNA-LNPs for preclinical or clinical evaluation.
“This adoption of novel science and innovative technology demonstrates Quotient Sciences’ commitment to accelerating drug development, with the potential to transform the development and manufacture of RNA-based drugs,” said Gareth Jenkins, VP, science and technology.
“This signals our entry into the development and acceleration of RNA-based drug products, with flexible, on-demand manufacture of RNA-based drug products and capacity for up to one million doses from the same machine in 24 hrs. Together with Centillion, we now look forward to working with our customers to support the preclinical to clinical transition of their RNA-based development candidates to bring new therapies to patients faster.”
“The Biofoundry-in-a-Box is…the key component of Centillion’s RNA-by-Design™ offering, for the delivery of regulatory ready, patient centric, and equitable access to advanced therapies,” said Harris Makatsoris, PhD, CEO at Centillion Technology. “The BiaB advantages over traditional methods of RNA manufacturing, include high throughput of high-quality pharmaceutical products, aligning with the rapid response needs of manufacturing accelerators as Quotient Sciences.”
